Loading company
Mangoceuticals, Inc.
MGRX · Nasdaq · ·
$0.45+21.1%Sep 29 close
- 1M
- +11.5%
- 6M
- +4.9%
- 1Y
- -79.5%
Mangoceuticals, Inc. is the 37th largest of 41 graded companies. Showing 5 of them, including MGRX itself.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Talkspace, Inc.TALK | D | — | $245.7M | 0.1% | — | — |
| Veeva Systems Inc.VEEV | A+ | $45.1B | $3.5B | 29.3% | — | 45.59 |
| Tempus AI, Inc.TEM | D- | $14.8B | $1.4B | -17.8% | -$263.2M | — |
| BrightSpring Health Services, Inc.BTSG | A | $11B | $14.4B | 2.5% | $402.4M | 33.55 |
| Mangoceuticals, Inc.MGRX | D- | $9.7M | $315.2K | -4,791.3% | — | — |
36 more health information services companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded Mangoceuticals, Inc. on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
MGRX · Nasdaq · ·
$0.45+21.1%Sep 29 close